Web Watch
Web Watch in One Page
Five questions will start to resolve in the next six months, each tied to a tension the verdict left open: whether Cigna Healthcare MCR holds inside the 83.7-84.7% guide through Q2/Q3 FY26; whether Evanko's September Investor Day reclaims a $7.0B+ FY27 Evernorth floor; whether Centene (19% of FY25 revenue; -$7.6B FY25 operating loss / -$6.7B net loss) carves specialty volume to AcariaHealth or reprices ahead of its 2029-2030 cliff; whether the Bernstein Litowitz Ascent class action survives motion to dismiss and forces expanded related-party disclosure; and whether CAA 2026 implementation plus Signature adoption track the bull's clearing-event read or the bear's structural margin reset.
Active Monitors
| Rank | Watch item | Cadence | Why it matters | What would be detected |
|---|---|---|---|---|
| 1 | Cigna Healthcare MCR and Q2/Q3 FY26 earnings prints | 1d | Every 100bps of MCR ≈ $700M pretax; bull's primary tripwire and the Q4 24 stop-loss credibility scar; Q1 FY26 printed 79.8% well below the 83.7-84.7% guide | Press releases, 8-Ks, earnings transcripts, broker target resets, sell-side commentary on Q2 (late Jul/early Aug) and Q3 (late Oct/early Nov) FY26 results |
| 2 | September 2026 Investor Day and Evanko's FY27 Evernorth framework | 1d | First multi-year framework under the new CEO; FY27 Evernorth adjusted OI guide of ≥$7.0B is the single most decisive variable in the variant case; eviCore disposition and capital-return algorithm also resolve here | Investor Day date confirmation, agenda, deck, transcript, and any pre-event capital-allocation or guidance signals from Brian Evanko after his July 1 transition |
| 3 | Centene PBM contract status, AcariaHealth in-housing, counterparty stress | 1d | 19% of FY25 group revenue (up from 16%) is the largest discrete operating risk in US managed care; Centene posted a -$7.6B FY25 operating loss (-$6.7B net loss) and runs AcariaHealth as a credible in-house specialty exit | Centene 8-Ks/10-K disclosures, RFP activity, AcariaHealth volume commentary, contract amendment signals, Centene financial-stress headlines, any public extension or repricing of the Express Scripts master contract |
| 4 | Bernstein Litowitz Ascent rebate-diversion class action and PBM enforcement | 1d | An adverse motion-to-dismiss ruling forces expanded related-party disclosure on the Swiss Ascent vehicle into the FY26 10-K and re-opens the SEC question on AR factoring — a 10-15% overlay haircut to fair value | Court docket movement, MTD ruling, settlement chatter, SEC comment-letter activity, Item 4.02 non-reliance 8-Ks, FTC follow-on action, new investor-rights firm filings |
| 5 | CAA 2026 PBM rebate pass-through implementation and Signature rebate-free adoption | 1d | Aug 2028 ERISA 100% rebate pass-through and Jan 2028 Part D list-price ban are dated, unconditional federal-law triggers; Signature client adoption is the bull's replacement-economics test (≥50% of PBS members by YE2028 is management's commitment) | Federal regulator rule-making, FTC Express Scripts consent-order phased milestones, HHS/CMS Part D guidance, Signature client wins, 2027 selling-season commentary, broker notes on PBM take-rate trajectory |
Why These Five
The verdict made the question explicit: the multiple is too cheap to short and the structural overhang is too live to own, with the decisive read — the FY27 Evernorth adjusted OI guide — not landing until February 2027. Until then, every datapoint that moves the debate sits in one of five buckets, and these five monitors cover all of them. Monitor 1 is the bull's primary insurance — the Q1 FY26 79.8% MCR print cleared the bar that broke Humana and CVS, but Q2 is the seasonally heavier test. Monitor 2 covers the highest-leverage decision moment of the next six months: the September Investor Day is when Evanko has to anchor either the bull's $7.0B+ FY27 Evernorth read or the bear's $6.9B floor. Monitor 3 covers the bear's strongest concrete claim — a 19% client whose own P&L is failing and who has an in-house exit. Monitor 4 covers the forensic overlay: the Ascent class action is the only event inside this window that can rebase reported PBS economics through expanded disclosure rather than operational performance. Monitor 5 covers the structural mechanic underlying the entire PBM repricing debate — federal law, FTC consent-order milestones, and Signature adoption are the three knobs that determine whether the rebate-free pivot is clearing event or margin cliff. No generic "latest news" monitor was added because the report's open questions are specific enough that broader coverage would dilute signal.